| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 04/29/2003 | US6555345 Papilloma viruses, agents for detecting them and for treating diseases caused by such viruses |
| 04/29/2003 | US6555344 Polynucleotides encoding SRE B2 receptor |
| 04/29/2003 | US6555343 Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
| 04/29/2003 | US6555342 Fusion protein delivery system and uses thereof |
| 04/29/2003 | US6555341 Gamma-aminobutyric acid (GABA); stably co-transfected eukaryotic cell line capable of expressing a human GABAa receptor which comprises a theta receptor subunit and at least one receptor subunit; drug screening |
| 04/29/2003 | US6555340 Receptor for advanced glycation endproduct (RAGE); nucleic acid, vector and host cell; use in field of drug screening |
| 04/29/2003 | US6555339 Altering human G protein-coupled receptors (GPCRs) by point mutation; use in drug screening |
| 04/29/2003 | US6555338 Given nucleotide sequence; use of polynucleotides and polypeptides in diagnostic assays, and possibly functional genomics |
| 04/29/2003 | US6555337 Protein/transcription factor in basic-helix-loop-helix (bHLH) gene family which plays role in cell determination; genetic engineering |
| 04/29/2003 | US6555322 Connective tissue growth factor (CTGF); drug screening for agents that modulate the activity of a CTGF receptor comprising the alpha 2- macroglobulin receptor |
| 04/29/2003 | US6555321 Methods for determining cell responses through EphB receptors |
| 04/29/2003 | US6555316 Human g35030 gene; diagnostic kits; recombinant host cells |
| 04/29/2003 | US6555313 Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| 04/29/2003 | US6555311 Hepatitis B variants exhibiting complete or partial resistance to nucleoside analogues and/or reduced interactivity with antibodies to viral surface components; use determining if a strain will be antiviral drug resistant |
| 04/29/2003 | US6555116 Hypo-allergenic pollen protein that has been treated with thioredoxin, nicotinamide adenine dinucleotide phosphate-thioredoxin reductase (NTR) and reduced nicotinamide adenine dinucleotide phosphate (NADPH). |
| 04/29/2003 | US6555115 Administering a polypeptide that contains at least one antigenic portion of a Chlamydia antigen to stimulate an immune response |
| 04/29/2003 | US6555114 Immunodominant human T-cell epitopes of hepatitis C virus |
| 04/29/2003 | US6555113 Elevating the ratio of circulating HDL to circulating LDL by administering a peptide conjugate of a helper T cell epitope portion linked to a B cell epitope portion; decrease in development of atherosclerotic lesions |
| 04/29/2003 | US6555111 Method of inhibiting the cytocidal effect of TNF with TNF receptor-specific antibodies |
| 04/29/2003 | US6555109 Non-toxic fraction isolated from the venom of Vipera xanthina |
| 04/29/2003 | US6555108 Implanting HSV-TK retrovirus producing cells to treat tumors |
| 04/29/2003 | US6555105 Method of treatment with a RANTES antagonist polypeptide |
| 04/29/2003 | US6555091 Polypeptide capable of reacting with antibodies of patients suffering from multiple sclerosis and uses |
| 04/29/2003 | CA2258502C Modified factor viii |
| 04/29/2003 | CA2159098C Isolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereof |
| 04/29/2003 | CA2121369C Inhibitors of dipeptidyl-aminopeptidase type iv |
| 04/29/2003 | CA2105804C Kainate-binding, human cns receptors of the eaa5 family |
| 04/29/2003 | CA2102208C Binding domains in notch and delta proteins |
| 04/29/2003 | CA1341428C Synthetic insecticidal crystal protein gene |
| 04/24/2003 | WO2003034275A2 Chimeric glycosylphosphatidylinositol containing peptides |
| 04/24/2003 | WO2003034149A1 Process and materials for formation of patterned films of functional materials |
| 04/24/2003 | WO2003034072A2 Diagnosis and therapy of conditions involving alms1 |
| 04/24/2003 | WO2003033808A2 Composition and method for treating diabetes |
| 04/24/2003 | WO2003033736A2 Fine mapping and application of dna markers linked to a gall midge resistance gene for marker-aided selection in rice |
| 04/24/2003 | WO2003033734A2 Diagnostic tests for the diagnosis of copper storage disease |
| 04/24/2003 | WO2003033723A2 Vectors for expressing multiple transgenes |
| 04/24/2003 | WO2003033720A2 Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |
| 04/24/2003 | WO2003033714A1 Nucleic acid sequences that induce early flowering |
| 04/24/2003 | WO2003033712A1 Chemically inducible promoters from barley and use thereof |
| 04/24/2003 | WO2003033707A1 Enzyme gene participating in the synthesis of polyester and process for producing polyester using the same |
| 04/24/2003 | WO2003033705A1 Transgenic organism expressing fungal mrp-like abc transporters |
| 04/24/2003 | WO2003033704A1 Gene of enzyme reactivating dna damaged by ultraviolet light using visible light |
| 04/24/2003 | WO2003033703A2 Human gtp-activator protein for rab-like gtpase |
| 04/24/2003 | WO2003033695A1 Method of purifying recombinant fused protein and method of producing protein using the same |
| 04/24/2003 | WO2003033694A1 Primers and method of detecting bacteria |
| 04/24/2003 | WO2003033693A1 Fluorescent protein |
| 04/24/2003 | WO2003033692A2 Use of the adenoviral e2 late promoter |
| 04/24/2003 | WO2003033682A1 Dna fpr expression of alpha i-antitrypsin in methylotropic yeast |
| 04/24/2003 | WO2003033677A2 Dimerized growth factor and materials and methods for producing it |
| 04/24/2003 | WO2003033675A2 Identification of binding partners for specific proteins |
| 04/24/2003 | WO2003033672A2 Nr3b nmda receptor subunit compositions and related methods |
| 04/24/2003 | WO2003033671A2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| 04/24/2003 | WO2003033667A2 Use of mx gtpases in the prognosis and treatment of cancer |
| 04/24/2003 | WO2003033666A2 Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes |
| 04/24/2003 | WO2003033665A2 Secreted protein, ztnf9 |
| 04/24/2003 | WO2003033664A2 Bone anti-resorptive compounds |
| 04/24/2003 | WO2003033663A2 Rankl mimics and uses thereof |
| 04/24/2003 | WO2003033662A2 Protection against oxidative stress and inflammation by a cytoprotective response element |
| 04/24/2003 | WO2003033661A2 Methods of using 279, a human g protein-coupled receptor |
| 04/24/2003 | WO2003033658A2 Neutrokine-alpha and neutrokine-alpha splice variant |
| 04/24/2003 | WO2003033655A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 04/24/2003 | WO2003033652A2 TUMOR ENDOTHELIAL MARKER 5α MOLECULES AND USES THEREOF |
| 04/24/2003 | WO2003033651A2 Compositions and methods for promoting nematode resistance in plants |
| 04/24/2003 | WO2003033650A2 Recombinant renilla reniformis system for bioluminescence resonance energy transfer |
| 04/24/2003 | WO2003033646A2 Compositions and methods for the modulation of viral maturation |
| 04/24/2003 | WO2003033645A2 Synthetic peptides and dna sequences for treatment of multiple sclerosis |
| 04/24/2003 | WO2003033536A2 G-protein coupled receptor |
| 04/24/2003 | WO2003033535A2 Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
| 04/24/2003 | WO2003033534A2 Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof |
| 04/24/2003 | WO2003033533A1 Microfluidized leishmania antigen and methods of making and using thereof |
| 04/24/2003 | WO2003033532A1 Anitmicrobial proteins, genes encoding the proteins and mehtod of using the same |
| 04/24/2003 | WO2003033531A1 S8 rRNA-BINDING PROTEIN FROM THE SMALL RIBOSOMAL SUBUNIT OF STAPHYLOCOCCUS AUREUS |
| 04/24/2003 | WO2003033530A2 Mycobacterial antigens expressed under high oxygen tension |
| 04/24/2003 | WO2003033528A1 Cyclic peptides as g-protein-coupled receptor antagonists |
| 04/24/2003 | WO2003033522A1 Isolation of lectins |
| 04/24/2003 | WO2003033520A2 Anticancer vaccine and diganostic methods and reagents |
| 04/24/2003 | WO2003033515A1 Compositions and methods for the therapy and diagnosis of acne vulgaris |
| 04/24/2003 | WO2003033513A1 Differentially expressed genes associated with obesity and type 2 diabetes |
| 04/24/2003 | WO2003033463A2 Multimerized enhancer domains for cell-specific expression |
| 04/24/2003 | WO2003033030A1 Pacap compositions and methods for tumor imaging and therapy |
| 04/24/2003 | WO2003033021A1 Use of peptide vectors to improve the immune response to antigens |
| 04/24/2003 | WO2003033017A1 Additive cytoprotective effects of two bioactive regions of pro-opiomelanocortin hormone |
| 04/24/2003 | WO2003033016A1 Use of neurotrophic factors for treating neurodegenerative diseases and cancer |
| 04/24/2003 | WO2003033011A2 Repetitive motifs from salivary proline rich proteins, mucin and collagen |
| 04/24/2003 | WO2003032964A2 Gap junctions and endothelial-derived hyperpolarizing factor (edhf) |
| 04/24/2003 | WO2003032913A2 Methods and compositions for targeting proteins across the blood brain barrier |
| 04/24/2003 | WO2003032899A2 Methods and materials for targeting and affecting selected cells |
| 04/24/2003 | WO2003032898A2 Modified human thymic stromal lymphopoietin |
| 04/24/2003 | WO2003032813A2 Methods for the treatment of carcinoma |
| 04/24/2003 | WO2003032810A2 Treatment and diagnosis of insulin resistant states |
| 04/24/2003 | WO2003032727A1 Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
| 04/24/2003 | WO2003005964A3 Recombinant vsv for the treatment of tumor cells |
| 04/24/2003 | WO2003004631A3 USE OF INHIBITORS OF EXPRESSION OR ACTIVITY OF p8/com1 FOR TREATING TUMORS. |
| 04/24/2003 | WO2002100887A3 Method for making insulin precursors and insulin precursor analogs |
| 04/24/2003 | WO2002099387A3 Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids |
| 04/24/2003 | WO2002098907A3 Cation conducting gabaa receptors and their use |
| 04/24/2003 | WO2002098457A3 Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses |
| 04/24/2003 | WO2002098441A3 Method of treating metabolic disorders using neuronatin polypeptides |
| 04/24/2003 | WO2002097072A3 Influenza vaccine composition |
| 04/24/2003 | WO2002090384A3 Antimicrobial polypeptide from aspergillus niger |